In Situ Hybridization Market to be Dominated by Fluorescent In Situ Hybridization through 2028.
The
growing prevalence of chronic diseases is expected to drive the growth of
Global In Situ Hybridization during the forecast period, 2024-2028.
According
to TechSci Research report, “In Situ Hybridization Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F”,
Global In Situ Hybridization market is expected to grow at an impressive rate
during the forecast period, 2024-2028. This can be ascribed to the
growing adoption of in situ hybridization products in managing genetic
disorders and cancer patients along with growing demand for quality medical
care across the region. Moreover, healthcare spending, rising government
initiatives on proteomics and genomics research and growing awareness regarding
the use of tissue diagnostic tests are the major factors driving the growth of
the market during the forecast period. Moreover, increasing initiatives by
market players such as partnerships, mergers and acquisitions for in situ
hybridization techniques will further boost the growth of the global In Situ
Hybridization market during the forecast period. Besides, governments around the
world are providing support for the development of healthcare industry,
including funding for research and development, which is expected to drive the
demand for In Situ Hybridization market during the forecast period.
However,
the high cost of In Situ Hybridization can slow down the growth of the global
In Situ Hybridization market during the forecast period. Moreover, in situ
hybridization is a complex technique that requires specialized expertise and
training to perform and interpret the results. The complexity of the technique
can make it challenging for some researchers and clinicians to adopt and
implement in their workflows. Similarly, limited sensitivity, alternative
techniques such as Polymerase Chain Reaction, Next Generation Sequencing
provide similar or complementary information and may be more widely adopted or
preferred by some researchers and clinicians which may hamper the growth of the
market during the forecast period.
Browse
over XX market data Figures spread through xx Pages and an in-depth TOC
on "Global In Situ Hybridization Market”
In Situ
Hybridization market can be segmented on the basis of product, technology,
application, end user and region.
Based on
technology, the global In Situ Hybridization market can be further divided into fluorescent in situ
hybridization v/s chromogenic in situ hybridization. The fluorescent in situ hybridization dominated
the market in 2022 and is expected to continue maintaining its dominance
throughout the forecast period. This can be ascribed to an increase in the use
of this techniques in diagnostic laboratories for cancer diagnosis and
research, as well as in the diagnosis of genetic disorders, infectious
diseases, and other conditions. Moreover, the adoption of FISH in clinical
diagnostics and research applications is increasing and is expected to create
lucrative growth during the forecast period.
Based on application, the
market is further segmented into cancer diagnostics, cytology, infectious diseases diagnostics,
neuroscience, and immunology. The
Cancer Diagnostics segment is expected to dominate during the forecast period
on account of the increasing high demand for Fluorescence In Situ Hybridization
in the detection of cellular and genetic markers in cancers such as HER2, ALK,
and ROS and the increasing adoption of personalized medicine and targeted
therapies.
Major
companies operating in the global In Situ Hybridization market are:
- Abbott Laboratories
- F.Hoffmann Roche AG.
- Thermo Fisher Scientific Inc.
- Danaher Corp.
- Agilent Technologies Inc.
- Biocare Medical LLC.
- Biotechne Corporation.
- Qiagen N.V
- Merck KGAA.
- Perkinelmer Inc
Recent
Development
- On July 7, 2021, Thermo
Fisher Scientific and Ortho Clinical Diagnostics announced a partnership to
promote and distribute Thermo Scientific MAS Quality Controls and LabLink xL
Quality Assurance Software for use with Ortho Clinical Diagnostics VITROS
analyzers.
- Sysmex Corporation
announced the signing of a Global Business Partnership Agreement with Roche
Diagnostics International Ltd., the diagnostic reagent business unit of F.
Hoffmann-La Roche, Ltd., on December 14, 2020.
- In July 2021, Merck entered
into immuno-oncology collaboration agreements with GlaxoSmithKline plc (GSK) in
the United Kingdom and Pfizer Inc. (Pfizer) in the United States.
- In March 2020, Agilent
Technologies Inc. announced the completion of its acquisition of BioTek
Instruments, a global leader in the design, manufacture, and distribution of
cutting-edge life science instrumentation.
- In March 2021, Thermo
Fisher Scientific Inc., a global leader in science service, announced the
release of the Thermo Scientific AerosolSense Sampler, a new surveillance
solution designed to provide rapid and highly reliable insight into the
presence of in-air pathogens such as SARS-CoV-2.
Download Free Sample Report
Customers
can also request for 10% free customization on this report.
“North
America is expected to dominate in the global In Situ Hybridization market
owing to the increase in funding for the development of research and healthcare
infrastructure and a rise in biomedical research activities across the region.
Similarly, increasing incidence of cancer and infectious diseases and growing
demand for personalized medicine is expected to create lucrative growth in the
market during the forecast period. Moreover, strong demand for early
cancer detection capabilities and rise in awareness among patients, and a surge
in per capita expenditure are expected to drive the growth of the market during
the forecast period. Furthermore, increasing occurrence of genetic disease and
disorder and growing demand for personalized testing kits is further expected
to create lucrative opportunities for market growth,” said Mr. Karan Chechi,
Research Director with TechSci Research, a research-based global management
consulting firm.
“In Situ
Hybridization Market -
Global Industry Size, Share, Trends, Opportunity, and Forecast,
2018-2028F” Segmented By Product
(Consumables, Instruments, Software), By Technology (Fluorescent in situ
hybridization v/s Chromogenic in situ hybridization), By Application (Cancer
Diagnostics, Cytology, Infectious Diseases Diagnostics, Neuroscience,
Immunology), By End User (Hospitals and Diagnostic laboratories, Academic &
Research institutes, Pharmaceutical & Biotechnology companies, Contract
Research Organizations), By Region and By Competition”, has evaluated the future growth potential of global In Situ
Hybridization market and provides statistics & information on market size,
structure, and future market growth. The report intends to provide cutting-edge
market intelligence and help decision-makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in the global In Situ
Hybridization market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Web:
https://www.techsciresearch.com